Filing Details

Accession Number:
0001415889-21-005014
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-28 20:06:52
Reporting Period:
2021-10-26
Accepted Time:
2021-10-28 20:06:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479419 Kala Pharmaceuticals Inc. KALA Pharmaceutical Preparations (2834) 270604595
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1710697 Hongming Chen C/O Kala Pharmaceuticals, Inc.
490 Arsenal Way, Suite 210
Watertown MA 02472
Chief Scientific Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-10-26 9,449 $1.80 225,566 No 4 S Direct
Common Stock Disposition 2021-10-27 21,051 $1.82 204,515 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.89, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  3. Includes 61,166 unvested RSUs.
  4. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.84, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.